Prior to the SARS-CoV-2 pandemic, antibiotic resistance was listed as the major global
health care priority. Some analyses, including the O'Neill report, have predicted that deaths …

Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment
of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix …

Abstract Treatment of invasive fungal infections (IFIs) remains challenging, because of the
limitations of the current antifungal agents (ie, mode of administration, toxicity, and drug-drug …

Fungal pathogens pose a global threat to human health, with Candida albicans among the
leading killers. Systematic analysis of essential genes provides a powerful strategy to …

Candida species are the leading cause of invasive fungal infections worldwide and are
associated with acute mortality rates of~ 50%. Mortality rates are further augmented in the …

Several new antifungals are currently in late-stage development, including those with novel
pharmacodynamics/mechanisms of action that represent new antifungal classes …

Fungal infections are on the rise, driven by a growing population at risk and climate change.
Currently available antifungals include only five classes, and their utility and efficacy in …

Invasive candidiasis (IC), due to the yeast pathogen Candida, is still a major cause of in-
hospital morbidity and mortality. The limited number of antifungal drug classes and the …

Introduction The epidemiology of invasive Candida infections is evolving. Infections caused
by non-albicans Candida spp. are increasing; however, the antifungal pipeline is more …

In many ways, fungal diseases are forgotten or neglected. Given the significantly lower
frequency compared to similar bacterial etiologies across the spectrum of infectious …